PRTT / Protect Pharmaceutical Corporation - Documents déposés auprès de la SEC, rapport annuel, procuration

PRTT / Protect Pharmaceutical Corp 15-12G - -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. PROTECT PHARMACEUTICAL CORP (Exact name of registrant as specified in its charter) 4876 Cecile Ave

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2019 Protect Pharmaceutical Corporation (Exact Name of Registrant as Specified in Charter) Nevada 001-54001 82-4148346 (State of incorporation) (Commission F

Resignation Letter

PRTT / Protect Pharmaceutical Corp

NT 10-K 1 nt10-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2018 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form

PRTT / Protect Pharmaceutical Corp (Quarterly Report)

10-Q 1 form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended June 30, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-54001 PROTECT PH

PRTT / Protect Pharmaceutical Corp (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended March 31, 2018 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-54001 PROTECT PHARMACEUTICAL CORPOR

PRTT / Protect Pharmaceutical Corp (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-54001 PROT

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2019 Protect Pharmaceuticals Corporation (Exact name of registrant as specified in its charter) Nevada 000-54001 27-1877179 (State or other jurisdiction of incorporat

PRTT / Protect Pharmaceutical Corp 10-K (Annual Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-54001 PROTECT PHARMACEUTICAL

PRTT / Protect Pharmaceutical Corp 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended September 30, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-54001 PROTECT PHARMACEUTICAL CO

PRTT / Protect Pharmaceutical Corp 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended June 30, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-54001 PROTECT PHARMACEUTICAL CORPORA

Certificate of Amendment – Share Authorization

Board Action Without Meeting of January 30, 2018

EX-1 2 ex1.htm Exhibit 1 to Board Action Without Meeting of January 30, 2018 Transactions Affirmed ● Loan: $25,000 from Audra M. Hajj to Protect Pharmaceutical on December 17, 2018 ● Misc. dates: Engagement or replacement of attorneys or auditors, at the CEO’s discretion, with written or other contract terms, again at the discretion of CEO Una J. Taylor. ● SEC 8-k Filing 12/10/2018, Document Date

Board Ratification

EX-3 4 ex3.htm Action Without Meeting by Shareholders of Protect Pharmaceuticals Corporation, a Nevada Business Corporation Now comes Una J. Taylor, owner of a majority of the stock of the above corporation, and takes the following actions without a meeting, pursuant to Nev. Rev. Stat. 78.310, and by Section 2.11 of the Bylaws of the Corporation, which allows action without meeting by action witho

Termination of a Material Definitive Agreement, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2019 Protect Pharmaceuticals Corporation (Exact name of registrant as specified in its charter) Nevada 000-54001 27-1877179 (State or other jurisdiction of incorporati

Board Action Without Meeting of January 30, 2019, Protect Pharmaceuticals Corporation

Exhibit 2 to Board Action Without Meeting of January 30, 2019, Protect Pharmaceuticals Corporation Actions Disaffirmed and/Or Cancelled Without Ever Having Had Legal Effect ● Press Release, 12/07/18: AES and OnliFunds Launch OnliChain focused $250 million Fund.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28TH, 2018 Protect Pharmaceutical Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-54001 82-4148346 (State of incorporation) (Commission File Number)

Director Retainer Agreement entered into between Protect Pharmaceutical Corporation. and Wajed Salam dated November 28, 2018.

EX-10.1 2 ex10-1.htm Exhibit 10.1 BOARD OF DIRECTORS RETAINER AGREEMENT THIS BOARD OF DIRECTORS RETAINER AGREEMENT (the “Agreement”) is made as of November 28nd, 2018, by and between Protect Pharmaceutical Corporation., a Nevada Corporation (the “Company”) and Wajed Salam (the “Director”) (collectively, the “Parties”). WHEREAS, the Company desires to retain the Director to serve as a member of the

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2018 Protect Pharmaceutical Corporation (Exact Name of Registrant as Specified in Charter) Nevada 001-54001 82-4148346 (State of incorporation) (Commission File Number) (IRS E

PRTT / Protect Pharmaceutical Corp SC 14F1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14f-1 INFORMATION STATEMENT PURSUANT TO SECTION 14(f) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 14f-1 THEREUNDER Protect Pharmaceutical Corporation (Name of Registrant as Specified in its Charter) Nevada 000-54001 82-4148346 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Id

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2018 Protect Pharmaceuticals Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-54001 82-4148346 (State of incorporation) (Commission File Number) (IRS

Protect Pharmaceutical Corporation FINANCIAL CODE OF ETHICS

EX-14.1 2 ex14-1.htm Exhibit 14.1 Protect Pharmaceutical Corporation FINANCIAL CODE OF ETHICS As a public company, it is of critical importance that Protect Pharmaceutical Corporation (PRTT) filings with the Securities and Exchange Commission be accurate and timely. Depending on their position with PRTT, employees may be called upon to provide information to assure that PRTT's public reports are c

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2017 Protect Pharmaceuticals Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-54001 27-1877179 (State of incorporation) (Commission File Number) (IRS

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2017 Protect Pharmaceuticals Corporation (Exact Name of Registrant as Specified in Charter) Nevada 000-54001 27-1877179 (State of incorporation) (Commission File Number) (IRS

PRTT / Protect Pharmaceutical Corp 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark one) x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarter Ended March 31, 2017 o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 000-54001 PROTECT PHARMACEUTICAL CORPORATION (Exact name of registrant as specified in its charter) Nevada 27-1877179 (State or other jurisdiction of incorporation or organization) (I.

Protect Pharmaceutical 0-Q

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

PRTT / Protect Pharmaceutical Corp 10-K (Annual Report)

10-K 1 prttform10kv2cleansgacomment.htm 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2016 o Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commissio

Protect Pharmaceutical (Quarterly Report)

10-Q 1 f10qseptember302016edgarjiev.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended September 30, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission

Protect Pharmaceutical 0-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File No. 000-54001 (Check One): CUSIP Number: 74364W 104 Form 10-K Form 20-F Form 11-K X Form 10-Q Form 10-D Form N-SAR Form N-CSR For Period Ended: September 30, 2016 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K Transition Report on Fo

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events

8-K 1 protectpharmaceuticalcorpora.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2016 Protect Pharmaceutical Corporation (Exact Name of Registrant as Specified in Charter) Nevada 001-54001 27-1877179 (State of i

Financial Code of Ethics

EX-14 2 exhibit141financialcodeofeth.htm Exhibit 14.1 Protect Pharmaceutical Corporation FINANCIAL CODE OF ETHICS As a public company, it is of critical importance that Protect Pharmaceutical Corporation (PRTT) filings with the Securities and Exchange Commission be accurate and timely. Depending on their position with PRTT, employees may be called upon to provide information to assure that PRTT's

Protect Pharmaceutical 4F1

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Protect Pharmaceutical (Quarterly Report)

10-Q 1 f10qjune302016vedgar5.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended June 30, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number

Protect Pharmaceutical (Quarterly Report)

10-Q 1 f10qjune302016vedgar5.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended June 30, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number

Protect Pharmaceutical /A (Annual Report)

10-K/A 1 f10kdec312015amend1vedgar2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A [Amendment No. 1] (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2015 o Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period

Protect Pharmaceutical (Quarterly Report)

10-Q 1 f10qmar312016v4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended March 31, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-5

Protect Pharmaceutical 0-Q

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Protect Pharmaceutical (Annual Report)

10-K 1 f10kdec312015vedgar6.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2015 o Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission File Num

Protect Pharmaceutical 0-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File No. 000-54001 CUSIP Number: 74364W 203 (Check One): X Form 10-K Form 20-F Form 11-K Form 10-Q Form 10-D Form N-SAR Form N-CSR For Period Ended: December 31, 2015 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K Transition Report on For

PRTT / Protect Pharmaceutical Corp / KCG AMERICAS LLC - PRTT 13 G/A 11-30-15 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment 1) Protect Pharmaceutical Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 74364W203 (CUSIP Number) November 30, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

10-Q 1 sept1510qproctectvedgar4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended September 30, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File

Unregistered Sales of Equity Securities

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2014 o Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54001 PROTECT PHARMACEU

Protect Pharmaceutical 0-K

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

PRTT / Protect Pharmaceutical Corp / KCG AMERICAS LLC - SCHEDULE 13G Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Initial Filing) Under the Securities Exchange Act of 1934 Protect Pharmaceutical Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 74364W203 (CUSIP Number) January 30, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan

TABLE OF CONTENTS SIGNATURES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended September 30, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-54001 PROTECT PHARMACEUT

PRTT / Protect Pharmaceutical Corp NT 10-Q - -

NT 10-Q 1 f12b25sept2014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File No. 000-54001 (Check One): CUSIP Number: 74364W 104 Form 10-K Form 20-F Form 11-K X Form 10-Q Form 10-D Form N-SAR Form N-CSR For Period Ended: September 30, 2013 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 4, 2014 PROTECT PHARMACEUTICAL CORPORTION (Exact name of registrant as specified in its charter) NEVADA 000-54001 27-1877179 (State or other jurisdiction (Commission (IRS Emp

PRTT / Protect Pharmaceutical Corp DEF 14C - -

DEF 14C 1 f14cinfostatementstocksplits.htm Commission File No. 000-54001 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [X] Defi

PRTT / Protect Pharmaceutical Corp PRE 14C - -

Converted by EDGARwiz Commission File No. 000-54001 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information St

Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

CLAIMS ASSIGNMENT AGREEMENT

ASSIGNMENT AGREEMENT CLAIMS ASSIGNMENT AGREEMENT THIS CLAIMS ASSIGNMENT AGREEMENT (the “Agreement”) is made and entered into as of the 19th day of September 2014, by and between Blue Cap Development Corp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

PRTT / Protect Pharmaceutical Corp NT 10-Q - -

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2013 o Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54001 PROTECT PHARMACEU

-

UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File No. 000-54001 CUSIP Number: 74364W 104 (Check One): X Form 10-K Form 20-F Form 11-K Form 10-Q Form 10-D Form N-SAR Form N-CSR For Period Ended: December 31, 2013 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K Transition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

-

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File No. 000-54001 (Check One): CUSIP Number: 74364W 104 Form 10-K Form 20-F Form 11-K X Form 10-Q Form 10-D Form N-SAR Form N-CSR For Period Ended: September 30, 2013 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K Transition Report on Fo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

-

NT 10-Q 1 f12b25jun2013draft1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File No. 000-54001 (Check One): CUSIP Number: 74364W 104 Form 10-K Form 20-F Form 11-K X Form 10-Q Form 10-D Form N-SAR Form N-CSR For Period Ended: June 30, 2013 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended March 31, 2013 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 333-180954 PROTECT PHARMACEUTICAL CORPORATION (Exact name of regis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2012 o Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54001 PROTECT PHARMACEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A #1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A #1 (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended September 30, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 333-180954 PROTECT PHARMACEUTICAL CORPORATION (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended June 30, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 333-180954 PROTECT PHARMACEUTICAL CORPORATION (Exact name of regist

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended June 30, 2012 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 333-180954 PROTECT PHARMACEUTICAL CORPORATION (Exact name of regist

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended March 31, 2012 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-54001 PROTECT PHARMACEUTICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2011 o Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54001 PROTECT PHARMAC

-

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

-

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

-

Converted by EDGARwiz PROTECT PHARMACEUTICAL CORPORATION 2681 Parleys Way, Ste. 204 Salt Lake City, UT 84109 October 5, 2012 United States Securities and Exchange Commission Division of Corporate Finance Attn: Joel Parker, Accounting Branch Chief Tabatha Akins, Staff Accountant Washington, D.C. 20549 RE: Protect Pharmaceutical Corporation Form 8-K Filed May 21, 2012 File Number 000-54001 Dear Mr.

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review -

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2011 o Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54001 PROTECT PHARMAC

-

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review -

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

SADLER, GIBB & ASSOCIATES, L.L.C. CERTIFIED PUBLIC ACCOUNTANTS Registered with the Public Company Accounting Oversight Board

PCA-CL-15: Letter from Auditor to SEC Relating to Non-reliance on Previously Issued Financial Statements or a Related Audit Re SADLER, GIBB & ASSOCIATES, L.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2011 o Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54001 PROTECT PHARMACEU

-

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

-

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 14, 2012 PROTECT PHARMACEUTICAL CORPORTION (Exact name of registrant as specified in its charter) NEVADA 000-54001 27-1877179 (State or other jurisdiction of incorporation) (

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers -

Converted by EDGARwiz UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Dr. Ram Sesha,

Exhibit 99.1 Dr. Ram Sesha, Chief Executive Officer, Protect Pharmaceutical Corporation. 116 Village Boulevard, Suite 300, Princeton, NJ 08540. Dear Ram, Owing to other preoccupations, I will be unable to serve on the Board of Directors of Protect. I therefore tender my resignation and would request you to confirm its acceptance. Sincerely, Dipak Chattaraj

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 23, 2011 PROTECT PHARMAC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 23, 2011 PROTECT PHARMACEUTICAL CORPORTION (Exact name of registrant as specified in its charter) NEVADA 000-54001 27-1877179 (State or other jurisdiction (Commission (IRS Em

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended September 30, 2011 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-54001 PROTECT PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File No. 000-54001 CUSIP Number: 74364W 104 (Check One): Form 10-K Form 20-F Form 11-K X Form 10-Q Form 10-D Form N-SAR Form N-CSR For Period Ended: September 30, 2011 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K Transition Report on Fo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended June 30, 2011 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-54001 PROTECT PHARMACEUTICAL

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2011 PROTECT PHARMACEUTICAL CORPORATION (Exact Name of Registrant as specified in charter) Nevada 000-54001 27-1877179 (State or other jurisdiction (Commission (IRS Employer of incorporat

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities of 1934

Commission File No. 000-54001 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement PROTECT PHARMACEUTICAL CORPORATIO

July 1, 2011

COVER LETTER July 1, 2011 Securities and Exchange Commission Attn: Jeffrey P. Riedler, Assistant Director Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 VIA: EDGAR Re: Protect Pharmaceutical Corporation Amendment No. 1 to Preliminary 14C (Filed June 23, 2011) SEC File No. 000-54001 Dear Mr. Riedler: In response to your letter dated June 30, 2011, the following information,

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities of 1934

Commission File No. 000-54001 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities of 1934 Check the appropriate box: x Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) o Definitive Information Statement PROTECT PHARMA

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities of 1934

Commission File No. 000-54001 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities of 1934 Check the appropriate box: x Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ¨ Definitive Information Statement PROTECT PHARMACEUTICL CORPORATION

Leonard E. Neilson A PROFESSIONAL CORPORATION

Leonard E. Neilson A PROFESSIONAL CORPORATION LEONARD E. NEILSON 8160 South Highland Drive, Suite 104 Attorney at Law Sandy, Utah 84093 Telephone: (801) 733-0800 Fax: (801) 733-0808 E-mail: [email protected] June 23, 2011 Securities and Exchange Commission Office of Document Control 100 F Street NE Washington, D.C. 20549 VIA: EDGAR Re: Protect Pharmaceutical Corporation File No. 000-54001 Prelim

INVESTMENT AGREEMENT

INVESTMENT AGREEMENT THIS INVESTMENT AGREEMENT (hereinafter referred to as the “Agreement”), dated as of June 16, 2011 by and between Protect Pharmaceutical Corp.

REGISTRATION RIGHTS AGREEMENT

REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (hereinafter referred to as the “Agreement”), dated June 16, 2011 by and between Protect Pharmaceutical Corporation, a Nevada corporation, with principal office at 116 Village Boulevard, Suite 200, Princeton, NJ 08540 (hereinafter referred to as the “Company”), and Kodiak Capital Group, LLC, a Delaware Limited Liability Company, with its principal office at 488 Madison Ave.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 17, 2011 PROTECT PHARMACEUTICAL CORPORTION (Exact name of registrant as specified in its charter) NEVADA 000-54001 27-1877179 (State or other jurisdiction (Commission (IRS Employ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended March 31, 2011 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-54001 PROTECT PHARMACEUTICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 11, 2011 PROTECT PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 11, 2011 PROTECT PHARMACEUTICAL CORPORTION (Exact name of registrant as specified in its charter) NEVADA 000-54001 27-1877179 (State or other jurisdiction (Commission (IRS Emplo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2010 o Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54001 Protect Pharmaceu

PATENT PURCHASE AGREEMENT

Exhibit 10.1 PATENT PURCHASE AGREEMENT This Patent Purchase Agreement ("Patent Purchase Agreement"), made and entered into this 19th day of January, 2011 (the “Effective Date”), is by and between Protect Pharmaceutical Corporation, a corporation organized and existing under and by virtue of the laws of the State of Nevada, having an office and place of business at 116 Village Boulevard, Suite 200,

Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 31, 2011 PROTECT PHARMACEUTICAL CORPORTION (Exact name of registrant as specified in its charter) NEVADA 000-54001 27-1877179 (State or other jurisdiction (Commission (IRS Emp

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 23, 2010 PROTECT PHARMACEUTICAL CORPORTION (Exact name of registrant as specified in its charter) NEVADA 000-54001 27-1877179 (State or other jurisdiction (Commission (IRS Em

December 23, 2010

Exhibit 99.1 December 23, 2010 Dear Dr Bernstein, You as board member of Protect Pharmacutical Corporation I feel that it is essential to write this letter to you. Based on the events of the last week, it is clear to me that I will not be allowed to perform my duties in the manner I deem necessary to serve the best interests of the company and it’s shareholders. Accordingly, I must resign my posit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended September 30, 2010 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-54001 PROTECT PHARMACEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 2)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 2) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended June 30, 2010 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-54001 PRO

Leonard E. Neilson A PROFESSIONAL CORPORATION

COVER LETTER Leonard E. Neilson A PROFESSIONAL CORPORATION LEONARD E. NEILSON 8160 South Highland Drive, Suite 104 Attorney at Law Sandy, Utah 84093 Telephone: (801) 733-0800 Fax: (801) 733-0808 E-mail: [email protected] September 22, 2010 Securities and Exchange Commission Office of Document Control 100 F Street NE Washington, D.C. 20549 VIA: EDGAR Re: Protect Pharmaceutical Corporation File No

Leonard E. Neilson A PROFESSIONAL CORPORATION

COVER LETTER Leonard E. Neilson A PROFESSIONAL CORPORATION LEONARD E. NEILSON 8160 South Highland Drive, Suite 104 Attorney at Law Sandy, Utah 84093 Telephone: (801) 733-0800 Fax: (801) 733-0808 E-mail: [email protected] September 22, 2010 Securities and Exchange Commission Attn: Tabatha Akins, Staff Accountant Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 VIA: EDGAR Re:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 5 FORM 10/A GENERAL FORM FOR REGISTRANTS OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 Protect Pharmaceutical Corporation (E

As filed with the Securities and Exchange Commission on September 22, 2010 Registration No.

Leonard E. Neilson A PROFESSIONAL CORPORATION LEONARD E. NEILSON 8160 South Highland Drive, Suite 104 Attorney at Law Sandy, Utah 84093 Telephone: (801) 733-0800 Fax: (801) 733-0808 E-mail: [email protected] September 22, 2010

COVER LETTER Leonard E. Neilson A PROFESSIONAL CORPORATION LEONARD E. NEILSON 8160 South Highland Drive, Suite 104 Attorney at Law Sandy, Utah 84093 Telephone: (801) 733-0800 Fax: (801) 733-0808 E-mail: [email protected] September 22, 2010 Securities and Exchange Commission Attn: Jeffrey P. Riedler, Assistant Director Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 VIA: ED

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 2, 2010 PROTECT PHARMACEUTICAL CORPORTION (Exact name of registrant as specified in its charter) NEVADA 000-54001 27-1877179 (State or other jurisdiction

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 4 FORM 10/A GENERAL FORM FOR REGISTRANTS OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 Protect Pharmaceutical Corporation (E

As filed with the Securities and Exchange Commission on September 8, 2010 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended June 30, 2010 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-54001 PRO

Leonard E. Neilson A PROFESSIONAL CORPORATION

COVER LETTER Leonard E. Neilson A PROFESSIONAL CORPORATION LEONARD E. NEILSON 8160 South Highland Drive, Suite 104 Attorney at Law Sandy, Utah 84093 Telephone: (801) 733-0800 Fax: (801) 733-0808 E-mail: [email protected] September 8, 2010 Securities and Exchange Commission Office of Document Control 100 F Street NE Washington, D.C. 20549 VIA: EDGAR Re: Protect Pharmaceutical Corporation File No.

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 2, 2010 PROTECT PHARMACEUTICAL CORPORTION (Exact name of registrant as specified in its charter) NEVADA 000-54001 27-1877179 (State or other jurisdiction (Commission (IRS Em

A PROFESSIONAL CORPORATION

COVER LETTER A PROFESSIONAL CORPORATION LEONARD E. NEILSON 8160 South Highland Drive, Suite 104 Attorney at Law Sandy, Utah 84093 Telephone: (801) 733-0800 Fax: (801) 733-0808 E-mail: [email protected] September 8, 2010 Securities and Exchange Commission Attn: Jeffrey P. Riedler, Assistant Director Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 VIA: EDGAR Re: Protect Phar

Leonard E. Neilson A PROFESSIONAL CORPORATION

COVER LETTER Leonard E. Neilson A PROFESSIONAL CORPORATION LEONARD E. NEILSON 8160 South Highland Drive, Suite 104 Attorney at Law Sandy, Utah 84093 Telephone: (801) 733-0800 Fax: (801) 733-0808 E-mail: [email protected] August 25, 2010 Securities and Exchange Commission Attn: Jeffrey P. Riedler, Assistant Director Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 VIA: EDGAR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 FORM 10/A GENERAL FORM FOR REGISTRANTS OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 Protect Pharmaceutical Corporation (E

As filed with the Securities and Exchange Commission on August 25, 2010 Registration No.

Leonard E. Neilson A PROFESSIONAL CORPORATION

COVER LETTER Leonard E. Neilson A PROFESSIONAL CORPORATION LEONARD E. NEILSON 8160 South Highland Drive, Suite 104 Attorney at Law Sandy, Utah 84093 Telephone: (801) 733-0800 Fax: (801) 733-0808 E-mail: [email protected] August 23, 2010 Securities and Exchange Commission Office of Document Control 100 F Street NE Washington, D.C. 20549 VIA: EDGAR Re: Protect Pharmaceutical Corporation File No. 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended June 30, 2010 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-54001 PROTECT PHARMACEUTICAL

Leonard E. Neilson A PROFESSIONAL CORPORATION LEONARD E. NEILSON Attorney at Law 8160 South Highland Drive, Suite 104 Sandy, Utah 84093 Telephone: (801) 733-0800 Fax: (801) 733-0808 E-mail: [email protected] August 6, 2010

COVER LETTER Leonard E. Neilson A PROFESSIONAL CORPORATION LEONARD E. NEILSON Attorney at Law 8160 South Highland Drive, Suite 104 Sandy, Utah 84093 Telephone: (801) 733-0800 Fax: (801) 733-0808 E-mail: [email protected] August 6, 2010 Securities and Exchange Commission Attn: Jeffrey P. Riedler, Assistant Director Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 VIA: EDGAR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 FORM 10/A GENERAL FORM FOR REGISTRANTS OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 Protect Pharmaceutical Corporation (E

As filed with the Securities and Exchange Commission on August 6, 2010 Registration No.

EMPLOYMENT AGREEMENT

Exhibit 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) made this 28th day of May 2010 by and between Protect Pharmaceutical Corporation, a Nevada corporation with offices in West Caldwell, New Jersey (the “Company”) and Bill Abajian, an individual residing in New Jersey [“Employee”). Company and Employee collectively referred to herein as Parties. WHEREAS, Employee and Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 FORM 10/A GENERAL FORM FOR REGISTRANTS OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 Protect Pharmaceutical Corporation (E

As filed with the Securities and Exchange Commission on July 21, 2010 Registration No.

Leonard E. Neilson A PROFESSIONAL CORPORATION

COVER LETTER Leonard E. Neilson A PROFESSIONAL CORPORATION LEONARD E. NEILSON 8160 South Highland Drive, Suite 104 Attorney at Law Sandy, Utah 84093 Telephone: (801) 733-0800 Fax: (801) 733-0808 E-mail: [email protected] July 21 2010 Securities and Exchange Commission Attn: Jeffrey P. Riedler, Assistant Director Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 VIA: EDGAR Re

Instrument defining rights of holders – Specimen Stock Certificate

NOT VALID UNLESS COUNTERSIGNED BY TRANSFER AGENT INCORPORATED UNDER THE LAWS OF THE STATE OF NEVADA CUSIP NUMBER 74364W 104 NUMBER SHARES Protect Pharmaceutical, Inc.

BY–LAWS PROTECT PHARMACEUTICAL CORPORATION

BY–LAWS OF PROTECT PHARMACEUTICAL CORPORATION Article I – OFFICES Article II – MEETINGS OF SHAREHOLDERS Article III – DIRECTORS Article IV – OFFICERS Article V – EXECUTION OF INSTRUMENTS, BORROWING OF MONEY AND DEPOSIT OF CORPORATE FUNDS Article VI – CAPITAL SHARES Article VII – EXECUTIVE COMMITTEE AND OTHER COMMITTEES Article VIII – INDEMNIFICATION, INSURANCE, AND OFFICER AND DIRECTOR CONTRACTS Article IX – FISCAL YEAR Article X – DIVIDENDS Article XI – AMENDMENTS ARTICLE I OFFICES Section 1.

Articles of Incorporation

DEAN HELLER Secretary of State 206 North Carson Street Carson City, NV 89701-4299 (775) 684 5708 Website: secretaryofstate.

Certificate of Amendment – Name Change 2010

DEAN HELLER Secretary of State 202 North Carson St. Carson City, NV 89701-4299 Document Number 20100270883-11 (775) 684-5708 File Date and Time 04/23/2010 5:00 PM Website: secretaryofstate.biz Entity Number E0449732006-8 Certificate of Amendment (PURSUANT TO NRS 78.385 and 78.390) Certificate of Amendment to Articles of Incorporation For Nevada Profit Corporations (Pursuant to NRS 78.385 and 78.39

Protect Pharmaceutical Corporation PRTT PATENT PORTFOLIO UPDATE

Protect Pharmaceutical Corporation PRTT PATENT PORTFOLIO UPDATE 1 Novel Tapentadol combinations for treating pain 61/004,029 dated November 23, 2007 Provisional for WO2009067703 Active 2 TAPENTADOL COMPOSITIONS (WO2009067703) PCT/US2008/0844 dated November 21, 2008 National Phase Due May 21, 2010 Active 3 Novel Slow Release Tapentadol Compositions 61/216, 399 Dated May 18, 2009 PCT (PRTT05182010)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRANTS OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 Protect Pharmaceutical Corporation (Exact name of regis

As filed with the Securities and Exchange Commission on June 8, 2010 Registration No.

PATENT ACQUISITION AGREEMENT

PATENT ACQUISITION AGREEMENT This Patent Acquisition Agreement (the “Agreement”) is entered into and effective as of February 12, 2010 (the “Effective Date”), by and among Nectid Inc.

Certificate of Amendment – Name Change 2006

DEAN HELLER Secretary of State 202 North Carson St. Entity Number E0449732006-8 Carson City, NV 89701-4299 Document Number 20060805378-59 (775) 684-5708 File Date and Time 12/15/2006 11:00:48AM Website: secretaryofstate.biz Certificate of Amendment (PURSUANT TO NRS 78.385 and 78.390) Certificate of Amendment to Articles of Incorporation For Nevada Profit Corporations (Pursuant to NRS 78.385 and 78

THIS EMPLOYMENT AGREEMENT IS DATED FEBRUARY 12, 2010

THIS EMPLOYMENT AGREEMENT IS DATED FEBRUARY 12, 2010 BETWEEN PRO-TECT INC ("PRTT"), a corporation incorporated pursuant to the laws of the State of Nevada, United States of America, (referred to as the "Corporation") - and – Ramesha Sesha, a resident of New Jersey at 9113 Taylor Court, West Windsor, NJ 08550, (referred to as the "Employee").

EMPLOYMENT AGREEMENT

EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) made this day of 2010 by and between Protect Pharmaceutical Corporation, a Nevada corporation with offices in , New Jersey (the “Company”) and Bill Abajian, an individual residing in , New Jersey [“Employee”).

Certificate of Amendment – Capitalization Change

DEAN HELLER Secretary of State 202 North Carson St. Entity Number E0449732006-8 Carson City, NV 89701-4299 Document Number 20060800014-61 (775) 684-5708 File Date and Time 12/13/2006 Website: secretaryofstate.biz Certificate of Amendment (PURSUANT TO NRS 78.385 and 78.390) Certificate of Amendment to Articles of Incorporation For Nevada Profit Corporations (Pursuant to NRS 78.385 and 78.390 - Afte

Leonard E. Neilson A PROFESSIONAL CORPORATION

COVER LETTER Leonard E. Neilson A PROFESSIONAL CORPORATION LEONARD E. NEILSON 8160 South Highland Drive, Suite 104 Attorney at Law Sandy, Utah 84093 Telephone: (801) 733-0800 Fax: (801) 733-0808 E-mail: [email protected] June 8, 2010 Securities and Exchange Commission Office of Document Control 100 F Street NE Washington, D.C. 20549 VIA: EDGAR Re: Protect Pharmaceutical Corporation Registration